Traders Are Skeptical About Bayer’s Chances With Monsanto: Chart

Monsanto Co. closed Wednesday at just $106.76 -- well below Bayer AG’s offer of $128 a share -- as wary traders remained skeptical that the deal will make it to completion. When you place the transaction among other megadeals from the past two years, it doesn’t look good: Both the Pfizer Inc.-Allergan Plc combination and Enterprise Products Partners LP’s bid for Williams Cos. were later terminated. While Anthem Inc.’s $48 billion takeover of Cigna Corp. is still possible, its spread has widened even further in recent months after U.S. regulators sued to block the deal.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE